| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Product revenues, net | 12,001.3 | 11,020.1 | NaN | NaN |
| Cost of sales-Product | 601.5 | 516.3 | NaN | NaN |
| Cost of sales-Royalty | 1,049.8 | 1,014.2 | NaN | NaN |
| Research expenses | 827.9 | 804.5 | NaN | NaN |
| Development expenses | 3,081.6 | 2,825.8 | NaN | NaN |
| Acquired in-process research and development expenses | 133 | 4,628.4 | NaN | NaN |
| Selling and other commercial expenses | 1,102.8 | 838.5 | NaN | NaN |
| General and administrative expenses | 650.3 | 625.8 | NaN | NaN |
| Intangible asset impairment charge | 379 | NaN | NaN | NaN |
| Interest income | 490.9 | 598.1 | NaN | NaN |
| Other segment items | 23.1 | 116.2 | NaN | NaN |
| Provision for income taxes | 690 | 784.1 | NaN | NaN |
| Income (loss) | 3,953.2 | -535.6 | 3,619.6 | 3,322 |
| Stock-based compensation expense | 685.9 | 698.5 | 581.2 | 491.3 |
| Depreciation and amortization expense | 209.8 | 207.2 | 181.3 | 148.3 |
| Intangible asset impairment charges | 379 | NaN | NaN | NaN |
| Deferred income taxes | -510.8 | -348.8 | -536.5 | -275.9 |
| Losses on equity securities | NaN | -57.7 | -0.6 | -149.1 |
| Decrease in fair value of contingent consideration | NaN | -0.5 | -51.6 | -57.5 |
| Other non-cash items, net | -113.4 | 56.3 | -8.4 | -11.8 |
| Accounts receivable, net | 347.3 | 99.3 | 84.1 | 358.6 |
| Inventories | 524.2 | 517.3 | 322.9 | 136.4 |
| Prepaid expenses and other assets | 396 | 200.3 | 545.7 | 326.4 |
| Accounts payable | 36.8 | 49.5 | 48.7 | 120.8 |
| Accrued expenses | -116.9 | 212.9 | 429.4 | 542.5 |
| Other liabilities | 148.5 | 39.7 | 208.9 | 498.9 |
| Investment in equity securities and notes receivable | NaN | NaN | 31 | NaN |
| Net cash provided by (used in) operating activities | 3,631.4 | -492.6 | 3,537.3 | 4,129.9 |
| Payments related to finite-lived intangible assets | NaN | NaN | 58 | NaN |
| Payment to acquire viacyte, inc., net of cash acquired | NaN | 0 | 0 | 295.9 |
| Purchases of available-for-sale debt securities | 6,396.5 | 7,438.2 | 3,786.5 | 692.7 |
| Sales and maturities of available-for-sale debt securities | 5,897.4 | 4,465.6 | 839.1 | 920 |
| Sale of equity securities | NaN | NaN | NaN | 0 |
| Purchases of property and equipment | 437.6 | 297.7 | 200.4 | 204.7 |
| Proceeds related to equity securities | 16 | 0 | 95.1 | NaN |
| Net payments related to finite-lived intangible assets | 0 | 187.7 | NaN | NaN |
| Acquisition of available-for-sale debt securities from alpine immune sciences, inc | 0 | 258 | NaN | NaN |
| Investment in equity securities and notes receivable | NaN | NaN | NaN | 47.8 |
| Other investing activities | 24.7 | 54 | NaN | NaN |
| Net cash used in investing activities | -945.4 | -3,770 | -3,141.7 | -321.1 |
| Issuances of common stock under benefit plans | 127.7 | 114.6 | 134.6 | 186.3 |
| Repurchases of common stock | 2,017.4 | 1,177.1 | 427.6 | 0 |
| Payments in connection with common stock withheld for employee tax obligations | 369.9 | 405 | 226.1 | 172 |
| Payments on finance leases | 5.4 | 33.6 | 44.9 | 85.5 |
| Proceeds from finance leases | NaN | NaN | NaN | 0 |
| Proceeds from finance leases and other financing activities | NaN | NaN | 1.8 | NaN |
| Other financing activities | 3.7 | 6.2 | NaN | 3.5 |
| Net cash used in financing activities | -2,261.3 | -1,494.9 | -562.2 | -67.7 |
| Effect of changes in exchange rates on cash | 90.9 | -42.6 | 26.9 | -29.2 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 515.6 | -5,800.1 | -139.7 | 3,711.9 |
| Cash and cash equivalents at beginning of period | 4,572.2 | 10,372.3 | 10,512 | 6,800.1 |
| Cash and cash equivalents at end of period | 5,087.8 | 4,572.2 | 10,372.3 | 10,512 |
VERTEX PHARMACEUTICALS INC MA (VRTX)
VERTEX PHARMACEUTICALS INC MA (VRTX)